PT-141 (Bremelanotide): Dosage, Effects & What the Research Says 2026

PT-141 holds a unique position in the peptide space: it's the only compound in this category with actual FDA approval for a sexual dysfunction indication (hypoactive sexual desire disorder in premenopausal women, marketed as Vyleesi). That means there's more controlled human clinical data available than for most research peptides, and also means the pharmacology is better understood. That said, most of the people using PT-141 are using it off-label, in doses and contexts outside the approved indication. Here's what the research actually says, what the community has learned, and how it differs from everything else you might be considering. As always, talk to your doctor before starting. PT-141 has real side effects and real contraindications. This is for informational purposes only.

PT-141 (bremelanotide) is a synthetic melanocortin receptor agonist: specifically, it acts on MC3R and MC4R in the central nervous system. This is mechanistically different from everything else in the sexual health peptide space. PDE5 inhibitors like sildenafil (Viagra) work peripherally: they increase blood flow to genital tissue by inhibiting an enzyme. They don't affect desire or arousal at the central level. PT-141 bypasses this entirely. It works at the brain level, activating pathways involved in sexual motivation and arousal. This explains why it works for both men and women (Viagra doesn't, meaningfully), and why it works even when the underlying issue is desire rather than mechanics. The distinction matters clinically: PT-141 can increase desire and arousal where sildenafil only improves erectile function. For people whose difficulty is interest rather than physical response, this is a fundamentally different mechanism.

PT-141 was approved by the FDA in June 2019 as Vyleesi, manufactured by AMAG Pharmaceuticals, for hypoactive sexual desire disorder in premenopausal women. The approval was based on two Phase 3 trials (Kingsberg et al., 2019). The primary endpoints were changes in satisfying sexual events and desire scores on the Female Sexual Function Index. The drug showed statistically significant improvements on both, though the effect sizes were moderate: about 0.5 additional satisfying sexual events per month and a 1.2-point improvement on the desire subscale. That's not a dramatic effect in absolute terms. But for a population where desire is the specific limiting factor, the clinical significance is real.

The FDA approval is for women only, but PT-141 is used extensively off-label in men, and there's a reasonable research foundation for it. Diamond et al. (2004) studied bremelanotide in men with erectile dysfunction and found that PT-141 produced erections in 80% of men who hadn't responded to sildenafil. Safarinejad (2008) reported similar results in men with psychogenic ED. The central mechanism explains why: men with erectile dysfunction caused by psychological or desire factors, rather than purely vascular issues, respond to the central arousal pathway. What most guides won't tell you: the men who benefit most from PT-141 are not those with vascular/physical ED. That population does better with sildenafil or tadalafil. PT-141's advantage in men is specifically where the issue involves desire, motivation, or response to erotic stimuli: the psychological component.

Most users report initial effects 45-90 minutes after subcutaneous injection. Some experience effects as early as 30 minutes; others report delayed onset of 2+ hours, particularly on first use. The effects can persist 6-12 hours. Don't re-dose based on perceived non-response in the first 60 minutes.

No: PT-141 is a dose-as-needed compound, not a daily therapy. The FDA label recommends no more than once every 24 hours. Daily use is associated with higher rates of hyperpigmentation due to melanocortin receptor activation. Most community protocols use it 1-2x weekly at most.

They work on different problems. PT-141 increases desire and arousal centrally; sildenafil improves erectile mechanics peripherally. If the problem is desire or arousal (psychological component), PT-141 has a genuine mechanistic advantage. If the problem is purely physical (vascular ED), sildenafil/tadalafil is likely more appropriate.

Start at the lowest effective dose (0.5-1 mg for first use). Don't inject on an empty stomach. The nausea typically peaks at 45-90 minutes and subsides within 2-3 hours. It tends to be less pronounced on subsequent uses once you've established your individual dose.

PT-141 is FDA-approved as Vyleesi for women with HSDD, which means it's a prescription drug. Research peptide vendors sell it as a research compound not for human use. The regulatory status of purchasing research compounds varies by jurisdiction: this is something to understand clearly before ordering.

1. Kingsberg et al. "Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder." Obstetrics & Gynecology, 2019. 2. Diamond et al. "Double-blind, placebo-controlled evaluation of PT-141, a melanocortin receptor agonist, in patients with erectile dysfunction." International Journal of Impotence Research, 2004. 3. Safarinejad, M.R. "Evaluation of the safety and efficacy of bremelanotide in female subjects with arousal disorder." Journal of Sexual Medicine, 2008. 4. FDA Prescribing Information: Vyleesi (bremelanotide) injection (2019) 5. Clayton et al. "Bremelanotide for female sexual dysfunctions in premenopausal women." Women's Health, 2016. 6. Simon et al. "Long-term safety and efficacy of bremelanotide for hypoactive sexual desire disorder." Obstetrics & Gynecology, 2019. 7. r/Peptides community reports: PT-141 user experience documentation (2024-2026)